医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Disclosure of data on Agaricus blazei mushroom, KA21′s immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infection, Toei Shinyaku

2022年08月12日 PM02:00
このエントリーをはてなブックマークに追加


 

TOKYO

On its website www.toeishinyaku.jp, Toei Shinyaku has disclosed data concerning the mechanism by which Agaricus blazei KA21 enhances immunity, its immunological enhancement effect as confirmed by human clinical trials, and candida and other types of fungal infection. Agaricus blazei KA21 product has been sold in the Japanese market as a supplement for the immune system for more than 25 years, and has won the support of many physicians.

About Agaricus blazei, brasiliensis, subrufescens

Agaricus blazei (also known as Agaricus blazei Murill, A. brasiliensis, A. subrufescens) is a medicinal mushroom. It is popular primarily in Asian countries (particularly Japan) as an ingredient of immune booster used in complementary and alternative medicine (CAM). Characteristics of Agaricus blazei such as safety and effectiveness vary significantly depending on the strain, cultivation method, and production region.

Agaricus KA21 (Common name: King Agaricus)

Agaricus KA21 is Agaricus blazei KA21 strain cultivated outdoors in Brazil under direct sunlight. Compared to regular Agaricus blazei cultivated in a dark greenhouse, Agaricus KA21 is large in size, contains an abundance of major ingredients such as beta-glucan and vitamin D, and offers an antioxidant activity level over five times greater. Outdoor cultivation is extremely difficult with small yield, therefore Agaricus KA21 is a rare commodity. Toei Shinyaku is the sole company in the world that sells it.

Toei Shinyaku Co.,Ltd.

Established in 1973, Toei Shinyaku is a Japanese manufacturer that specializes in R&D activities, as well as the manufacture and sale of Agaricus KA21. Toei Shinyaku has conducted research on Agaricus KA21 for over 25 years and presented 32 international papers on its findings; making it the company with the greatest research results out of all Japanese Agaricus blazei manufacturers. Toei Shinyaku discloses evidence supporting its product, Agaricus KA21, on its official homepage. Details include the safety of human clinical trials of Agaricus KA21, ability to strengthen the immune system, alleviate fatigue, improve hair loss and gray hair, and prevent fungal infection. Data also includes the effect of Agaricus KA21 found through trials on mice; such as reducing side effects of anticancer drugs, hair growth benefits, and enhanced wound healing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220807005053/en/

CONTACT

Toei Shinyaku Co.,Ltd.

Akitomo Motoi

info@toeishinyaku.jp

Cross-Border EC website: www.toeishinyaku.jp

For business inquiry including wholesales and OEM: www.agaricus.co.jp

Main Products: Akkerman Slim etc.

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続